Oct 5, 2021 | Filed Securities Cases
Kehoe Law Firm, P.C. is investigating whether Camber Energy, Inc. (“Camber” or the “Company”) (NYSE American: CEI) violated federal securities laws.
Camber investors should be aware that on October 5, 2021, Kerrisdale Capital issued a report which stated, among other things, that “Camber is a defunct oil producer that has failed to file financial statements with the SEC since September 2020, is in danger of having its stock delisted next month, and just fired its accounting firm in September. Its only real asset is a 73% stake in Viking Energy, an OTC-traded company with negative book value and a going-concern warning that recently violated the maximum-leverage covenant on one of its loans. (For a time, it also had a fake CFO – long story.)”
On this news, shares of Camber dropped almost 51% to close at $1.53 per share. Post-market on October 5, 2021, Camber’s share price dropped another 17.65% to $1.26 per share, thereby further injuring Camber investors.
CAMBER ENERGY INVESTORS WITH LOSSES GREATER THAN $25,000 WHO WISH TO DISCUSS KEHOE LAW FIRM’S SECURITIES CLASS ACTION INVESTIGATION OR HAVE QUESTIONS ABOUT POTENTIAL LEGAL CLAIMS SHOULD CONTACT EITHER JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected].
Oct 5, 2021 | Filed Securities Cases
Kehoe Law Firm, P.C. is investigating whether Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT) violated federal securities laws.
During the morning of October 4, 2021, Owlet stock fell more than 30%, on the news that the Company notified investors that Owlet received an FDA warning letter concerning the improper marketing of its Smart Sock medical device product.
The Company stated in an SEC filing that “[o]n October 1, 2021, Owlet . . . received a Warning Letter, dated October 1, 2021 (the ‘Warning Letter’), from the United States Food and Drug Administration (‘FDA’).”
According to Owlet:
The Warning Letter asserts that the Company’s marketing of its Owlet Smart Sock product (the ‘Smart Sock’) in the United States renders the Smart Sock a medical device requiring premarket clearance or approval from FDA, and that the Company has not obtained such clearance or approval in violation of the Federal, Food, Drug, and Cosmetic Act. The Warning Letter requests that the Company take prompt action to address the alleged violations. Among other things, the Warning Letter requests the Company cease commercial distribution of the Smart Sock for uses in measuring blood oxygen saturation and pulse rate where such metrics are intended to identify or diagnose desaturation and bradycardia using an alarm functionality to notify users that measurements are outside of preset values. The Warning Letter also identifies certain marketing claims that FDA believes render the Smart Sock a medical device.
OWLET INVESTORS WITH SIGNIFICANT FINANCIAL LOSSES WHO WISH TO DISCUSS KEHOE LAW FIRM’S SECURITIES CLASS ACTION INVESTIGATION OR HAVE QUESTIONS ABOUT POTENTIAL LEGAL CLAIMS SHOULD CONTACT EITHER JOHN KEHOE, ESQ., (215) 792-6676, EXT. 801, [email protected], OR MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected].
